Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program
ADELAIDE, AUS, Jul 22, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
Yvonne Lungerhausen, CEO, Avance Clinical said:
"Avance Clinical is very pleased to be working with Atossa Therapeutics again on their second COVID-19 Therapeutic Development Program. Atossa is a valued long-term client that clearly understands the excellence in clinical research available in Australia, and the many benefits of conducting studies in the region."
According to Atossa Therapeutics:
AT-301 is Atossa's proprietary formula intended for nasal administration in patients immediately following diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. It is intended for at-home use to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person's immune system can more effectively fight SARS-CoV-2 (coronavirus). Atossa also intends to conduct testing to determine whether AT-301 can be used as a prophylaxis to prevent or mitigate SARS-CoV-2.
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation.
"Our AT-301 nasal spray program is being developed for COVID-19 patients who are not hospitalized, which complements our AT-H201 program being developed for COVID-19 patients on ventilators," commented Steven Quay, M.D., Ph.D., President and CEO of Atossa. "Many COVID-19 patients are infected via the nasal passage, which makes a nasal spray therapy potentially very attractive. Collectively, the components of AT-301 are believed to replicate a 'vaccine-like mechanism' to help maintain a protective mucosal barrier within the nasal cavity with anti-viral properties that may lead to lower infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in the nasal cavity and upper respiratory tract. We may eventually develop AT-301 as a prophylaxis to reduce risk of being infected with COVID-19. For example, it could be taken as a daily vaccine-like treatment for people at higher-risk, such as TSA workers, emergency medical professionals and hospital personnel," concluded Dr. Quay.
An application to commence the study has been submitted to the relevant institutional review board (IRB) and local regulatory authority in Australia which must be approved before commencement of the study. Pending these approvals, Atossa expects that the study will commence this quarter. Adequate and well-controlled studies to demonstrate safety and efficacy must be successfully completed and regulatory approvals must be obtained before AT-301 may be commercialized. Atossa has filed provisional patent applications on AT-301 to treat patients diagnosed with, or to prevent, COVID-19 via nasal spray.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.
See full announcement here https://tinyurl.com/y46rcp33
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5-6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Source: Avance Clinical
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
DOCOMO to Conduct Open RAN Field Trials with Ooredoo, Smart and StarHub
Feb 27, 2024 19:53 JST
CleverTap partners with Zoomcar to drive customer engagement on their app
Feb 27, 2024 18:00 JST
NEC Selected by NTT DOCOMO as a Virtualized Radio Access Network (vRAN) Vendor
Feb 26, 2024 17:54 JST
Fujitsu and Celonis Expand Strategic Global Partnership
Feb 26, 2024 15:40 JST
Mitsubishi Corporation's Sale of Exportadora de Sal, S.A. de C.V., a Salt Production Company in Mexico
Feb 26, 2024 14:29 JST
'MMVO,' Mazda's Production Base in Mexico Marks its 10th Anniversary
Feb 26, 2024 14:00 JST
Mitsubishi Electric Building Solutions to Supply Elevators and Escalators for New Capital Relocation Project in Indonesia
Feb 26, 2024 11:00 JST
Clear Mobitel Successfully Deploys NEC 5G SA Cloud Native Core Network to Accelerate the Adoption of Innovative 5G Solutions in the UK and the Channel Islands
Feb 22, 2024 17:13 JST
NEC UPF Achieves Industry-Leading High Performance in 5G Core Networks, reaching 1.3Tbps Throughput
Feb 22, 2024 16:10 JST
DOCOMO and NTT Expand 6G Collaborations with SK Telecom and Rohde & Schwarz
Feb 22, 2024 15:33 JST
Successful demonstration of computing and mobile networks convergence to provide diverse services in the 6G era
Feb 22, 2024 13:18 JST
Fujitsu introduces "Uvance Wayfinders", expanded and strengthened consulting capabilities to deliver cross-industry business value
Feb 22, 2024 12:05 JST
Fujitsu delivers new supercomputer system to Japan Meteorological Agency to improve prediction accuracy for typhoons and torrential rain
Feb 21, 2024 16:38 JST
MHI Group Presents "Best Innovation 2023" Awards for Activities that Contribute to Protecting the Environment
Feb 21, 2024 16:28 JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 21, 2024 15:26 JST
NEC, Arm, Qualcomm, Red Hat, and Hewlett Packard Enterprise demonstrate Open vRAN and 5G Core UPF using Arm-based CPUs
Feb 21, 2024 14:09 JST
NEC launches new User Plane Function (UPF) product for telecom operators, aiming to achieve networks for the Beyond 5G/6G era
Feb 21, 2024 11:33 JST
TANAKA to Provide Pure Gold, Pure Silver, and Pure Bronze Medals for the Tokyo Marathon 2024
Feb 21, 2024 04:00 JST
Fujitsu collaborates with QuTech in development of new technology for freezing electronics to control diamond spin qubits
Feb 20, 2024 21:28 JST
NTT DOCOMO and SK Telecom Release White Paper on Base Station Equipment Utilizing Virtualization Technology
Feb 20, 2024 15:32 JST